ChromaDex Corporation - CDXC STOCK NEWS

ChromaDex Corp. (NASDAQ: CDXC) has expanded its patent portfolio for dihydronicotinamide riboside (NRH) with U.S. Patent 11,584,770, securing composition claims for purities over 90% chemical and 98% beta. This patent bolsters ChromaDex's leadership in the NAD+ precursor sector, allowing for future innovations in health supplements and pharmaceuticals. Preclinical studies suggest NRH is a potent NAD+ precursor, potentially outperforming existing options. The patent offers protection until 2034, enhancing the commercial viability of NRH and related products.

ChromaDex (NASDAQ: CDXC) provided an update on its intellectual property following a U.S. Court of Appeals decision affirming the invalidity of the 807 Dartmouth patent. The company asserts this judgment will not materially impact its nicotinamide riboside (NR) business, as it holds new patents obtained last year, ensuring protection for NR for at least the next 10 years. The patents cover methods of making NR and its various salt forms. ChromaDex emphasizes the strength of its brand, Tru Niagen®, backed by rigorous scientific studies. Looking ahead, the company plans to announce innovations in the coming months.

ChromaDex Corp. (NASDAQ:CDXC) announced positive results from its first-ever human clinical trial on combined metabolic activator (CMA) supplementation for Alzheimer's disease (AD) patients. The study, detailed in the peer-reviewed journal Translational Neurodegeneration, involved 60 patients and showed a 29% improvement in cognitive function compared to only 14% in the placebo group after 84 days. CMA, which includes the proprietary niagen® ingredient alongside L-carnitine and others, also enhanced liver and kidney health markers. ChromaDex plans to initiate a Phase 3 study for further research into CMA as a therapeutic option for AD.

ChromaDex Corp. (NASDAQ:CDXC) announced results from a pioneering five-month clinical study on its proprietary ingredient, Niagen® (nicotinamide riboside or NR). The study, involving 20 identical twin pairs, demonstrated that NR supplementation significantly improved muscle mitochondrial biogenesis, satellite cell differentiation, and gut microbiota composition. Results were published in Science Advances, marking a milestone as the longest NR supplementation study to date. NR increased mitochondrial DNA by ~30% and showed well-tolerance. However, the study had limitations, including a lack of parallel placebo arm for BMI-discordant twins, prompting further investigations.

ChromaDex Corp. (NASDAQ: CDXC) appointed Dr. Vilhelm Bohr to its Scientific Advisory Board. Dr. Bohr, a leading researcher in aging and neurodegenerative diseases, has over 590 publications and specialized in the effects of nicotinamide riboside (NR) on age-related conditions. His past research through ChromaDex's External Research Program has resulted in significant findings regarding NR's role in mitochondrial dysfunction and neurodegeneration. Dr. Bohr aims to explore further benefits of NR at ChromaDex.

ChromaDex Corp. (NASDAQ:CDXC) appointed Brianna Gerber as the new Chief Financial Officer, effective January 1, 2023. Gerber has over 20 years of experience in finance and investor relations, having served as Senior VP of Finance at ChromaDex since August 2022. CEO Rob Fried praised her leadership and commitment to achieving an EBITDA-positive business. Gerber expressed excitement about leading the company towards profitable growth and operational efficiency.

ChromaDex Corp. (NASDAQ:CDXC) announced new findings supporting the efficacy of its proprietary Niagen^® (nicotinamide riboside or NR) in enhancing neurodegenerative biomarkers associated with aging. A recent peer-reviewed study found that NR supplementation significantly increased NAD+ levels in neuron-derived extracellular vesicles and reduced biomarkers linked to Alzheimer’s disease, like Aβ42. This research builds on previous studies supporting NR’s benefits for cognitive health and sets the stage for future trials, including one focused on older adults with mild cognitive impairment.

ChromaDex Corp. (NASDAQ:CDXC) announced that the U.S. FDA has determined that nicotinamide mononucleotide (NMN) cannot be marketed as a dietary supplement, as it has been first investigated as a drug since November 4, 2022. This decision impacts ChromaDex's NMN offerings, while its proprietary ingredient Niagen®, a form of nicotinamide riboside (NR), remains a viable NAD+ precursor backed by over 20 clinical studies. ChromaDex continues its focus on NAD+ research and has established extensive partnerships for its CERP™ program.

ChromaDex Corp. (NASDAQ:CDXC) reported Q3 2022 net sales of $17.1 million, reflecting a 1% decline from Q3 2021. Strong gross margin stood at 59.8%. The net loss improved to $1.0 million or $(0.01) per share, a significant reduction from $8.8 million in Q3 2021. Adjusted EBITDA loss of $1.2 million shows a $5.1 million improvement. The company anticipates high single-digit revenue growth for 2022, targeting cash flow break-even in Q4. Strategic partnerships in China and with Nestlé Health Science were secured.